01779
114.9001.29%
$HENGRUI PHARMA(01276.HK) rose three percentage points, $LONGBIO-B(01779.HK) and $3SBIO(01530.HK) also saw slight gains. This batch of innovative drug stocks in Hong Kong showed slight strength, following the recovery in sentiment around innovative drugs going global and AI drug discovery. $Direxion S&P Biotech Bull 3X(LABU.US) also rose three percentage points, showing similar popularity in the US biotech sector.
Only small-cap US biotechs like $Eloxx Pharmaceuticals(ELOX.US) basically didn't move; without a catalyst, they just lie flat. Innovative drugs are climbing out of the trough of the past two years. This batch of Hong Kong stocks has low valuations and their elasticity makes them more worth following than large-cap US biotechs.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.